array(40) {
  [0]=>
  string(4) "1633"
  ["article_id"]=>
  string(4) "1633"
  [1]=>
  string(65) "Ertugliflozin Seems Safe, Effective for Type 2 Diabetes Treatment"
  ["article_title"]=>
  string(65) "Ertugliflozin Seems Safe, Effective for Type 2 Diabetes Treatment"
  [2]=>
  string(150) "THURSDAY, Jan. 17, 2019 -- Ertugliflozin appears safe and effective at improving long-term glycemic control among adults with type 2 diabetes mellitus"
  ["short_description"]=>
  string(150) "THURSDAY, Jan. 17, 2019 -- Ertugliflozin appears safe and effective at improving long-term glycemic control among adults with type 2 diabetes mellitus"
  [3]=>
  string(246) "THURSDAY, Jan. 17, 2019 -- Ertugliflozin appears safe and effective at improving long-term glycemic control among adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin, according to a study published online Jan. 7 in..."
  ["description"]=>
  string(246) "THURSDAY, Jan. 17, 2019 -- Ertugliflozin appears safe and effective at improving long-term glycemic control among adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin, according to a study published online Jan. 7 in..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(199) "https://www.drugs.com/news/ertugliflozin-seems-safe-effective-type-2-diabetes-79809.html?utm_source=ddc&utm_medium=rss&utm_campaign=Ertugliflozin+Seems+Safe%2C+Effective+for+Type+2+Diabetes+Treatment"
  ["blog_url"]=>
  string(199) "https://www.drugs.com/news/ertugliflozin-seems-safe-effective-type-2-diabetes-79809.html?utm_source=ddc&utm_medium=rss&utm_campaign=Ertugliflozin+Seems+Safe%2C+Effective+for+Type+2+Diabetes+Treatment"
  [15]=>
  string(19) "2019-01-17 20:00:19"
  ["add_date"]=>
  string(19) "2019-01-17 20:00:19"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:17"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2192"
  ["article_id"]=>
  string(4) "2192"
  [1]=>
  string(80) "Bio-Thera Solutions partners with Cipla Limited to market bevacizumab biosimilar"
  ["article_title"]=>
  string(80) "Bio-Thera Solutions partners with Cipla Limited to market bevacizumab biosimilar"
  [2]=>
  string(152) "Bio-Thera Solutions Ltd announced that it has reached a licensing agreement with Cipla Limited for its bevacizumab biosimilar, under which Cipla will"
  ["short_description"]=>
  string(152) "Bio-Thera Solutions Ltd announced that it has reached a licensing agreement with Cipla Limited for its bevacizumab biosimilar, under which Cipla will"
  [3]=>
  string(738) "Bio-Thera Solutions Ltd announced that it has reached a licensing agreement with Cipla Limited for its bevacizumab biosimilar, under which Cipla will have exclusive rights to distribute and market the drug in select emerging markets. BAT-1706 is a mAb biosimilar to Genentech’s Avastin which is currently approved for six indications including metastatic colorectal cancer, recurrent glioblastoma and non-squamous non-small cell lung cancer. Bio-Thera’s BAT-1706 is currently in a global Phase III study in patients with previously untreated advanced non-squamous non-small cell […]"
  ["description"]=>
  string(738) "Bio-Thera Solutions Ltd announced that it has reached a licensing agreement with Cipla Limited for its bevacizumab biosimilar, under which Cipla will have exclusive rights to distribute and market the drug in select emerging markets. BAT-1706 is a mAb biosimilar to Genentech’s Avastin which is currently approved for six indications including metastatic colorectal cancer, recurrent glioblastoma and non-squamous non-small cell lung cancer. Bio-Thera’s BAT-1706 is currently in a global Phase III study in patients with previously untreated advanced non-squamous non-small cell […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "43"
  ["rss_id"]=>
  string(2) "43"
  [14]=>
  string(61) "http://feedproxy.google.com/~r/BiosimilarNews/~3/oaYyAw3LDlM/"
  ["blog_url"]=>
  string(61) "http://feedproxy.google.com/~r/BiosimilarNews/~3/oaYyAw3LDlM/"
  [15]=>
  string(19) "2019-01-17 17:36:26"
  ["add_date"]=>
  string(19) "2019-01-17 17:36:26"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:41"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:41"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1610"
  ["article_id"]=>
  string(4) "1610"
  [1]=>
  string(32) "Health Highlights: Jan. 17, 2019"
  ["article_title"]=>
  string(32) "Health Highlights: Jan. 17, 2019"
  [2]=>
  string(153) "Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:&#nlDoctor at Ohio Hospital Gave Potentially Letha"
  ["short_description"]=>
  string(153) "Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:&#nlDoctor at Ohio Hospital Gave Potentially Letha"
  [3]=>
  string(250) "Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:&#nlDoctor at Ohio Hospital Gave Potentially Lethal Doses of Painkillers to Patients&#nlA doctor at an Ohio hospital was fired after an internal..."
  ["description"]=>
  string(250) "Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:&#nlDoctor at Ohio Hospital Gave Potentially Lethal Doses of Painkillers to Patients&#nlA doctor at an Ohio hospital was fired after an internal..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "5"
  ["rss_id"]=>
  string(1) "5"
  [14]=>
  string(147) "https://www.drugs.com/news/health-highlights-jan-17-2019-79801.html?utm_source=ddc&utm_medium=rss&utm_campaign=Health+Highlights%3A+Jan.+17%2C+2019"
  ["blog_url"]=>
  string(147) "https://www.drugs.com/news/health-highlights-jan-17-2019-79801.html?utm_source=ddc&utm_medium=rss&utm_campaign=Health+Highlights%3A+Jan.+17%2C+2019"
  [15]=>
  string(19) "2019-01-17 15:01:47"
  ["add_date"]=>
  string(19) "2019-01-17 15:01:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:16"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1611"
  ["article_id"]=>
  string(4) "1611"
  [1]=>
  string(47) "Health Tip: Starting a Healthy Weight Loss Plan"
  ["article_title"]=>
  string(47) "Health Tip: Starting a Healthy Weight Loss Plan"
  [2]=>
  string(153) "-- More than 70 percent of U.S. adults are overweight or obese, the National Institute of Diabetes and Digestive and Kidney Diseases says.&#nlAre you one"
  ["short_description"]=>
  string(153) "-- More than 70 percent of U.S. adults are overweight or obese, the National Institute of Diabetes and Digestive and Kidney Diseases says.&#nlAre you one"
  [3]=>
  string(254) "-- More than 70 percent of U.S. adults are overweight or obese, the National Institute of Diabetes and Digestive and Kidney Diseases says.&#nlAre you one of them?&#nlBefore starting a weight loss plan, you should visit your doctor. The first questions..."
  ["description"]=>
  string(254) "-- More than 70 percent of U.S. adults are overweight or obese, the National Institute of Diabetes and Digestive and Kidney Diseases says.&#nlAre you one of them?&#nlBefore starting a weight loss plan, you should visit your doctor. The first questions..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "5"
  ["rss_id"]=>
  string(1) "5"
  [14]=>
  string(175) "https://www.drugs.com/news/health-tip-starting-healthy-weight-loss-plan-79794.html?utm_source=ddc&utm_medium=rss&utm_campaign=Health+Tip%3A+Starting+a+Healthy+Weight+Loss+Plan"
  ["blog_url"]=>
  string(175) "https://www.drugs.com/news/health-tip-starting-healthy-weight-loss-plan-79794.html?utm_source=ddc&utm_medium=rss&utm_campaign=Health+Tip%3A+Starting+a+Healthy+Weight+Loss+Plan"
  [15]=>
  string(19) "2019-01-17 15:01:18"
  ["add_date"]=>
  string(19) "2019-01-17 15:01:18"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:16"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1612"
  ["article_id"]=>
  string(4) "1612"
  [1]=>
  string(32) "Health Tip: Eat Less, Enjoy More"
  ["article_title"]=>
  string(32) "Health Tip: Eat Less, Enjoy More"
  [2]=>
  string(153) "-- A key to successful dieting is to enjoy your food more, while eating less, the U.S. Department of Agriculture says.&#nlYour meals should include all o"
  ["short_description"]=>
  string(153) "-- A key to successful dieting is to enjoy your food more, while eating less, the U.S. Department of Agriculture says.&#nlYour meals should include all o"
  [3]=>
  string(255) "-- A key to successful dieting is to enjoy your food more, while eating less, the U.S. Department of Agriculture says.&#nlYour meals should include all of the food groups while limiting sugar, salt and saturated fat, the agency says.&#nlThe USDA offers..."
  ["description"]=>
  string(255) "-- A key to successful dieting is to enjoy your food more, while eating less, the U.S. Department of Agriculture says.&#nlYour meals should include all of the food groups while limiting sugar, salt and saturated fat, the agency says.&#nlThe USDA offers..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "5"
  ["rss_id"]=>
  string(1) "5"
  [14]=>
  string(148) "https://www.drugs.com/news/health-tip-eat-less-enjoy-more-79795.html?utm_source=ddc&utm_medium=rss&utm_campaign=Health+Tip%3A+Eat+Less%2C+Enjoy+More"
  ["blog_url"]=>
  string(148) "https://www.drugs.com/news/health-tip-eat-less-enjoy-more-79795.html?utm_source=ddc&utm_medium=rss&utm_campaign=Health+Tip%3A+Eat+Less%2C+Enjoy+More"
  [15]=>
  string(19) "2019-01-17 15:01:12"
  ["add_date"]=>
  string(19) "2019-01-17 15:01:12"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:16"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1716"
  ["article_id"]=>
  string(4) "1716"
  [1]=>
  string(102) "FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes"
  ["article_title"]=>
  string(102) "FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes"
  [2]=>
  string(150) "PARIS and THE WOODLANDS, TX – January 17, 2019 – The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Admin"
  ["short_description"]=>
  string(150) "PARIS and THE WOODLANDS, TX – January 17, 2019 – The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Admin"
  [3]=>
  string(246) "PARIS and THE WOODLANDS, TX – January 17, 2019 – The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of whether the overall benefits of..."
  ["description"]=>
  string(246) "PARIS and THE WOODLANDS, TX – January 17, 2019 – The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of whether the overall benefits of..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(197) "https://www.drugs.com/nda/zynquista_190117.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Advisory+Committee+Votes+on+Zynquista+%28sotagliflozin%29+as+Treatment+for+Adults+with+Type+1+Diabetes"
  ["blog_url"]=>
  string(197) "https://www.drugs.com/nda/zynquista_190117.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Advisory+Committee+Votes+on+Zynquista+%28sotagliflozin%29+as+Treatment+for+Adults+with+Type+1+Diabetes"
  [15]=>
  string(19) "2019-01-17 13:01:10"
  ["add_date"]=>
  string(19) "2019-01-17 13:01:10"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1660"
  ["article_id"]=>
  string(4) "1660"
  [1]=>
  string(71) "Allergan, St. Regis Tribe Seek SCOTUS Review of Sovereign Immunity Case"
  ["article_title"]=>
  string(71) "Allergan, St. Regis Tribe Seek SCOTUS Review of Sovereign Immunity Case"
  [2]=>
  string(158) "&#nl        Allergan and the St. Regis Mohawk Tribe have asked the Supreme Court to reverse a federal appeals court’s decision to bar a controversial t"
  ["short_description"]=>
  string(158) "&#nl        Allergan and the St. Regis Mohawk Tribe have asked the Supreme Court to reverse a federal appeals court’s decision to bar a controversial t"
  [3]=>
  string(247) "&#nl        Allergan and the St. Regis Mohawk Tribe have asked the Supreme Court to reverse a federal appeals court’s decision to bar a controversial tactic from being used as patent protection against inter partes reviews (IPRs).&#nl      "
  ["description"]=>
  string(247) "&#nl        Allergan and the St. Regis Mohawk Tribe have asked the Supreme Court to reverse a federal appeals court’s decision to bar a controversial tactic from being used as patent protection against inter partes reviews (IPRs).&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(109) "https://www.fdanews.com/articles/189905-allergan-st-regis-tribe-seek-scotus-review-of-sovereign-immunity-case"
  ["blog_url"]=>
  string(109) "https://www.fdanews.com/articles/189905-allergan-st-regis-tribe-seek-scotus-review-of-sovereign-immunity-case"
  [15]=>
  string(19) "2019-01-17 07:28:16"
  ["add_date"]=>
  string(19) "2019-01-17 07:28:16"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:21"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1661"
  ["article_id"]=>
  string(4) "1661"
  [1]=>
  string(91) "FDA Committee Endorses Amgen’s Postmenopausal Osteoporosis BLA, Recommends Black Box"
  ["article_title"]=>
  string(91) "FDA Committee Endorses Amgen’s Postmenopausal Osteoporosis BLA, Recommends Black Box"
  [2]=>
  string(158) "&#nl        An FDA advisory committee on Wednesday approved the risk-benefit profile of Amgen’s romosozumab, a monoclonal antibody for treatment of ost"
  ["short_description"]=>
  string(158) "&#nl        An FDA advisory committee on Wednesday approved the risk-benefit profile of Amgen’s romosozumab, a monoclonal antibody for treatment of ost"
  [3]=>
  string(178) "&#nl        An FDA advisory committee on Wednesday approved the risk-benefit profile of Amgen’s romosozumab, a monoclonal antibody for treatment of osteoporosis.&#nl      "
  ["description"]=>
  string(178) "&#nl        An FDA advisory committee on Wednesday approved the risk-benefit profile of Amgen’s romosozumab, a monoclonal antibody for treatment of osteoporosis.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(122) "https://www.fdanews.com/articles/189904-fda-committee-endorses-amgens-postmenopausal-osteoporosis-bla-recommends-black-box"
  ["blog_url"]=>
  string(122) "https://www.fdanews.com/articles/189904-fda-committee-endorses-amgens-postmenopausal-osteoporosis-bla-recommends-black-box"
  [15]=>
  string(19) "2019-01-17 07:27:24"
  ["add_date"]=>
  string(19) "2019-01-17 07:27:24"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:21"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1662"
  ["article_id"]=>
  string(4) "1662"
  [1]=>
  string(61) "FDA Revises Guidance for Sponsors of Rare Disease Drug Trials"
  ["article_title"]=>
  string(61) "FDA Revises Guidance for Sponsors of Rare Disease Drug Trials"
  [2]=>
  string(153) "&#nl        As the partial government shutdown grinds on, the FDA resumed issuing guidance on Wednesday with a revised draft guidance to help sponsors of"
  ["short_description"]=>
  string(153) "&#nl        As the partial government shutdown grinds on, the FDA resumed issuing guidance on Wednesday with a revised draft guidance to help sponsors of"
  [3]=>
  string(227) "&#nl        As the partial government shutdown grinds on, the FDA resumed issuing guidance on Wednesday with a revised draft guidance to help sponsors of rare disease treatments conduct more effective clinical trials.&#nl      "
  ["description"]=>
  string(227) "&#nl        As the partial government shutdown grinds on, the FDA resumed issuing guidance on Wednesday with a revised draft guidance to help sponsors of rare disease treatments conduct more effective clinical trials.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(101) "https://www.fdanews.com/articles/189903-fda-revises-guidance-for-sponsors-of-rare-disease-drug-trials"
  ["blog_url"]=>
  string(101) "https://www.fdanews.com/articles/189903-fda-revises-guidance-for-sponsors-of-rare-disease-drug-trials"
  [15]=>
  string(19) "2019-01-17 07:26:33"
  ["add_date"]=>
  string(19) "2019-01-17 07:26:33"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:21"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1757"
  ["article_id"]=>
  string(4) "1757"
  [1]=>
  string(195) "vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study"
  ["article_title"]=>
  string(195) "vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study"
  [2]=>
  string(150) "HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translat"
  ["short_description"]=>
  string(150) "HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translat"
  [3]=>
  string(251) "HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small..."
  ["description"]=>
  string(251) "HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/vtv-therapeutics-announces-publication-comprehensive-data-science-translational-medicine-detailing-18060.html?utm_source=ddc&utm_medium=rss&utm_campaign=vTv+Therapeutics+Announces+Publication+of+Comprehensive+Data+in+Science+Translational+Medicine+Detailing+the+"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/vtv-therapeutics-announces-publication-comprehensive-data-science-translational-medicine-detailing-18060.html?utm_source=ddc&utm_medium=rss&utm_campaign=vTv+Therapeutics+Announces+Publication+of+Comprehensive+Data+in+Science+Translational+Medicine+Detailing+the+"
  [15]=>
  string(19) "2019-01-17 04:01:46"
  ["add_date"]=>
  string(19) "2019-01-17 04:01:46"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1634"
  ["article_id"]=>
  string(4) "1634"
  [1]=>
  string(64) "Dermatologists' Rx for Antibiotics Dropped From 2008 to 2016"
  ["article_title"]=>
  string(64) "Dermatologists' Rx for Antibiotics Dropped From 2008 to 2016"
  [2]=>
  string(154) "WEDNESDAY, Jan. 16, 2019 -- Dermatologists' use of antibiotics to treat inflammatory skin conditions like acne and rosacea is decreasing, according to"
  ["short_description"]=>
  string(154) "WEDNESDAY, Jan. 16, 2019 -- Dermatologists' use of antibiotics to treat inflammatory skin conditions like acne and rosacea is decreasing, according to"
  [3]=>
  string(258) "WEDNESDAY, Jan. 16, 2019 -- Dermatologists' use of antibiotics to treat inflammatory skin conditions like acne and rosacea is decreasing, according to a study published online Jan. 16 in JAMA Dermatology.&#nlJohn S. Barbieri, M.D., from the University..."
  ["description"]=>
  string(258) "WEDNESDAY, Jan. 16, 2019 -- Dermatologists' use of antibiotics to treat inflammatory skin conditions like acne and rosacea is decreasing, according to a study published online Jan. 16 in JAMA Dermatology.&#nlJohn S. Barbieri, M.D., from the University..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(191) "https://www.drugs.com/news/dermatologists-rx-antibiotics-dropped-2008-2016-79793.html?utm_source=ddc&utm_medium=rss&utm_campaign=Dermatologists%27+Rx+for+Antibiotics+Dropped+From+2008+to+2016"
  ["blog_url"]=>
  string(191) "https://www.drugs.com/news/dermatologists-rx-antibiotics-dropped-2008-2016-79793.html?utm_source=ddc&utm_medium=rss&utm_campaign=Dermatologists%27+Rx+for+Antibiotics+Dropped+From+2008+to+2016"
  [15]=>
  string(19) "2019-01-17 03:00:49"
  ["add_date"]=>
  string(19) "2019-01-17 03:00:49"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:17"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1635"
  ["article_id"]=>
  string(4) "1635"
  [1]=>
  string(56) "Adoption of Advanced Health IT Capabilities Inconsistent"
  ["article_title"]=>
  string(56) "Adoption of Advanced Health IT Capabilities Inconsistent"
  [2]=>
  string(150) "WEDNESDAY, Jan. 16, 2019 -- Adoption of advanced health information technology (HIT) capabilities is inconsistent across health care systems, with ele"
  ["short_description"]=>
  string(150) "WEDNESDAY, Jan. 16, 2019 -- Adoption of advanced health information technology (HIT) capabilities is inconsistent across health care systems, with ele"
  [3]=>
  string(252) "WEDNESDAY, Jan. 16, 2019 -- Adoption of advanced health information technology (HIT) capabilities is inconsistent across health care systems, with electronic health record (EHR) standardization being the strongest predictor of advanced capabilities,..."
  ["description"]=>
  string(252) "WEDNESDAY, Jan. 16, 2019 -- Adoption of advanced health information technology (HIT) capabilities is inconsistent across health care systems, with electronic health record (EHR) standardization being the strongest predictor of advanced capabilities,..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(188) "https://www.drugs.com/news/adoption-advanced-health-capabilities-inconsistent-79790.html?utm_source=ddc&utm_medium=rss&utm_campaign=Adoption+of+Advanced+Health+IT+Capabilities+Inconsistent"
  ["blog_url"]=>
  string(188) "https://www.drugs.com/news/adoption-advanced-health-capabilities-inconsistent-79790.html?utm_source=ddc&utm_medium=rss&utm_campaign=Adoption+of+Advanced+Health+IT+Capabilities+Inconsistent"
  [15]=>
  string(19) "2019-01-17 03:00:48"
  ["add_date"]=>
  string(19) "2019-01-17 03:00:48"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:17"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}